DSMB recommends CNS Pharma's Berubicin trial continue unmodified after interim analysis

CNS Pharmaceuticals, Inc.

DSMB recommended continuation of Berubicin vs. Lomustine Phase 2/3 trial in recurrent GBM based on comparable overall survival.
Enrollment expected to complete early Q1 2024; primary endpoint is overall survival.
CEO John Climaco stated recommendation reflects acceptable efficacy and safety as defined in protocol.
FDA has granted Fast Track and Orphan Drug Designation for Berubicin for malignant glioma.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.